Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus

NCT01546558 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01546558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01546558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2012
Completion date
March 31, 2012
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus